We are live on ! Find out more
WST icon

West Pharmaceutical

573 hedge funds and large institutions have $18.8B invested in West Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 199 increasing their positions, 210 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more call options, than puts

Call options by funds: $20M | Put options by funds: $6.87M

110% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 48

19% more capital invested

Capital invested by funds: $15.8B → $18.8B (+$2.98B)

10% more funds holding

Funds holding: 523573 (+50)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

5% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 210

1.26% less ownership

Funds ownership: 94.11%92.85% (-1.3%)

Holders
573
Holders Change
+50
Holders Change %
+9.56%
% of All Funds
11.56%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
101
Increased
199
Reduced
210
Closed
48
Calls
$20M
Puts
$6.87M
Net Calls
+$13.1M
Net Calls Change
+$2.64M
Name Holding Trade Value Shares
Change
Change in
Stake
SI
451
Stephens Inc
Arkansas
$279K +$2.38K +9 +0.9%
MAP
452
Moody Aldrich Partners
Massachusetts
$268K -$70.9K -268 -22%
IIC
453
Integrated Investment Consultants
Michigan
$268K -$67.2K -254 -21%
OC
454
Oppenheimer & Co
New York
$264K +$2.65K +10 +1%
SCA
455
Snowden Capital Advisors
New York
$264K +$254K +959 New
AA
456
ALPS Advisors
Colorado
$261K -$124K -467 -33%
PRC
457
Pearl River Capital
Michigan
$261K +$251K +950 New
EA
458
Emerald Advisers
Pennsylvania
$256K
CCA
459
Checchi Capital Advisers
California
$254K -$46.3K -175 -16%
Voloridge Investment Management
460
Voloridge Investment Management
Florida
$254K +$245K +925 New
NICM
461
Neo Ivy Capital Management
New York
$249K +$240K +906 New
CBFP
462
Cedar Brook Financial Partners
Ohio
$245K -$6.35K -24 -3%
GLA
463
Great Lakes Advisors
Illinois
$244K -$13.9M -52,490 -98%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
464
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$240K +$231K +873 New
DILIC
465
Dai-ichi Life Insurance Company
Japan
$238K -$12.7K -48 -5%
P
466
Pitcairn
Pennsylvania
$237K -$10.1K -38 -4%
Bank Julius Baer & Co
467
Bank Julius Baer & Co
Switzerland
$236K -$9.26K -35 -4%
PAA
468
Peregrine Asset Advisers
Oregon
$234K +$226K +853 New
OTPPB
469
Ontario Teachers' Pension Plan Board
Ontario, Canada
$233K +$224K +846 New
MYAM
470
Meiji Yasuda Asset Management
Japan
$225K -$37K -140 -15%
LS
471
Livforsakringsbolaget Skandia
Sweden
$220K
EDRIA
472
Edmonds Duncan Registered Investment Advisors
Kansas
$220K +$212K +800 New
AWM
473
AE Wealth Management
Kansas
$217K +$209K +791 New
HSA
474
HBK Sorce Advisory
Pennsylvania
$216K +$208K +786 New
CAM
475
Cresset Asset Management
Illinois
$212K -$80.7K -305 -28%

WST Hedge Fund Activity: Q3 2020 in Review

573 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2020, worth a combined $18.8B — up 19% from $15.8B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new WST positions and 48 closed out — a net gain of 53 holders — while 199 added to existing stakes and 210 trimmed.

The largest buyer was Invesco, adding an estimated $123M. The largest seller was T. Rowe Price Associates, cutting an estimated $223M.

  • 573 institutional investors held West Pharmaceutical (WST) as of Q3 2020, up from 523 in Q2 2020.
  • Funds reported $18.8B of West Pharmaceutical stock for Q3 2020, up 19% quarter-over-quarter.
  • 101 funds opened new West Pharmaceutical positions in Q3 2020 and 48 closed out, a net change of +53 holders.
  • The largest West Pharmaceutical buyer in Q3 2020 was Invesco, an estimated $123M added.
  • The largest West Pharmaceutical seller in Q3 2020 was T. Rowe Price Associates, an estimated $223M sold.

Based on aggregated 13F filings for Q3 2020.